Recommended
Recommended
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

2.250 +0.030 (+1.35%)
Streaming Delayed Price Updated: 10:02 AM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,540
Open 2.200
Bid (Size) 2.230 (1)
Ask (Size) 2.260 (16)
Prev. Close 2.220
Today's Range 2.200 - 2.280
52wk Range 0.8332 - 5.390
Shares Outstanding 38,245,287
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in September Investor and Industry Conferences
From Pyxis Oncology
Via GlobeNewswire

Performance

YTD
+33.1%
+33.1%
1 Month
+69.2%
+69.2%
3 Month
+108.3%
+108.3%
6 Month
+145.9%
+145.9%
1 Year
-38.7%
-38.7%

More News

Read More
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Via Benzinga
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
Via Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Via Benzinga
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Via Benzinga
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire

Frequently Asked Questions

Is Pyxis Oncology, Inc. - Common Stock publicly traded?
Yes, Pyxis Oncology, Inc. - Common Stock is publicly traded.
What exchange does Pyxis Oncology, Inc. - Common Stock trade on?
Pyxis Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pyxis Oncology, Inc. - Common Stock?
The ticker symbol for Pyxis Oncology, Inc. - Common Stock is PYXS on the Nasdaq Stock Market
What is the current price of Pyxis Oncology, Inc. - Common Stock?
The current price of Pyxis Oncology, Inc. - Common Stock is 2.250
When was Pyxis Oncology, Inc. - Common Stock last traded?
The last trade of Pyxis Oncology, Inc. - Common Stock was at 10/01/25 10:02 AM ET
What is the market capitalization of Pyxis Oncology, Inc. - Common Stock?
The market capitalization of Pyxis Oncology, Inc. - Common Stock is 86.05M
How many shares of Pyxis Oncology, Inc. - Common Stock are outstanding?
Pyxis Oncology, Inc. - Common Stock has 86M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.